SCHEMBL22556783

SCHEMBL22556783

Cc1nc(N)nc(SCc2ncc(-c3cc(Cl)ccc3Cl)o2)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 3/20 0.40
HTR2B P41595 1/20 0.39
PDE4D Q08499 1/20 0.39
HPGD P15428 3/20 0.36
ALDH1A1 P00352 3/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
USP2 O75604 1/20 0.36
CYP1A2 P05177 1/20 0.34
CYP2C19 P33261 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
LMNA P02545 2/20 0.33
NPSR1 Q6W5P4 2/20 0.33
TSHR P16473 2/20 0.33
AGPAT2 O15120 1/20 0.33
HSP90AB1 P08238 1/20 0.33
MAPT P10636 2/20 0.32
HTT P42858 2/20 0.32
PTPN1 P18031 1/20 0.32
TDP1 Q9NUW8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29391453 1.00 HSP90AA1 (0.40) HSP90AA1HTR2BPDE4DHPGDALDH1A1
SCHEMBL27218843 0.88 HSP90AA1 (0.42) HSP90AA1HPGDALDH1A1SMN1; SMN2USP2
SCHEMBL29393818 0.88 HSP90AA1 (0.37) HSP90AA1HTR2BPDE4DHPGDALDH1A1
SCHEMBL22556729 0.88 HSP90AA1 (0.37) HSP90AA1HTR2BPDE4DHPGDALDH1A1
SCHEMBL27218816 0.87 HSP90AA1 (0.41) HSP90AA1HPGDALDH1A1SMN1; SMN2USP2
SCHEMBL22570656 0.87 KMT2A (0.44) HSP90AA1HTR2BPDE4DHPGDALDH1A1
SCHEMBL22556715 0.85 HTR2B (0.37) HSP90AA1HTR2BPDE4DHPGDALDH1A1
SCHEMBL29391010 0.85 HTR2B (0.37) HSP90AA1HTR2BPDE4DHPGDALDH1A1
SCHEMBL27218824 0.85 MEN1 (0.41) HSP90AA1HTR2BPDE4DHPGDALDH1A1
SCHEMBL22556755 0.85 HTR2B (0.36) HSP90AA1HTR2BPDE4DHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4232448-B1 AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR Halo Therapeutics Ltd (GB) 2025-05-07 EP claimed
EP-3956323-B1 OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1 Halo Therapeutics Ltd (GB) 2025-03-05 EP claimed
EP-4232448-B1 AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR Halo Therapeutics Ltd (GB) 2025-05-07 EP disclosed
EP-3956323-B1 OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1 Halo Therapeutics Ltd (GB) 2025-03-05 EP disclosed
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor Halo Therapeutics Ltd (GB) 2024-05-16 US disclosed
CN-116745289-A Agonists of free fatty acid receptor 1 and their use in diseases associated with said receptor 奥洛治疗有限公司 2023-09-12 CN disclosed
EP-3956323-A1 OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1 Gbiotech S.À.R.L. (CH) 2022-02-23 EP disclosed
WO-2020211956-A1 OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1 GBIOTECH S.À.R.L. (CH) 2020-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor FFAR1, FFAR2, FFAR3 HSP90AA1 3354/4885HTR2B 879/4885PDE4D 2899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.